Preliminary results of a phase 1 study showed favorable safety and tolerability of ribociclib, both concurrently with platinum and taxane chemotherapy and as maintenance therapy, with encouraging antitumor activity in patients with recurrent platinum-sensitive ovarian cancer Read More ›

Final analysis of the NOVA trial supports the long-term progression-free survival benefit and safe use of niraparib beyond first progression for maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer. Read More ›

Results of the phase 2 APPROVE trial demonstrated significant prolongation of progression-free survival with the addition of apatinib to PLD in patients with platinum-resistant or refractory recurrent ovarian cancer, with an adverse event profile consistent with that previously described for apatinib and PLD. Read More ›

Results of a placebo-controlled, phase 2 study (MORAb-003-011/ENGOT-ov27) indicate that the addition of farletuzumab to platinum-based chemotherapy was not superior to placebo/chemotherapy in improving progression-free survival or other efficacy parameters in patients with platinum-sensitive recurrent ovarian cancer in first relapse who had low alemtuzumab CA-125 levels. Read More ›

Olaparib was more cost-effective, compared with niraparib, as maintenance therapy for patients with recurrent platinum-sensitive ovarian cancer, as determined by a model-based analysis. Read More ›

This review outlines treatment sequencing considerations for patients with recurrent ovarian cancer. Read More ›

Findings of a national survey of US ovarian cancer programs identified several patient care deficits, including a greater need for the integration of palliative care, social work, dietetics, and financial counseling, and the expansion of clinical trials and genetic testing/counseling. Read More ›

Results of the C-MOnGene study support the adoption of a collaborative oncogenetic model that provides flexible, patient-centered, and efficient genetic counseling and testing for hereditary breast and ovarian cancer and serves as an example for other institutions to incorporate these aspects into their oncology care. Read More ›

Results from a retrospective analysis indicate that health education, using a clinical nursing pathway, results in a more effective understanding of ovarian cancer, reduced psychological burden, improved sleep quality, decreased incidence of complications, improved self-care agency, and improved quality of life among patients with ovarian cancer. Read More ›

The findings of a prospective study suggest that immunologic response to SARS-CoV-2 vaccination is lower among patients with ovarian cancer who are receiving treatment compared with healthy volunteers, indicating that such patients should maintain precautions against COVID-19 despite vaccination. Read More ›

Page 2 of 3


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: